TalPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Talquetamab in the Real World (Japan)

TalPioneer - Japan: Panel Interview of ONcology practices with Emergent Experience of Talquetamab in the Real World (Japan) - TalPioneer Japan

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059842

Enrollment

Registered

2025-12-01

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or refractory multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.18+ years of age at the time of the study participation. 2.Board certified in oncology or hematology and currently practicing medicine in Japan. 3.Japanese-language proficient. 4.Provides verbal consent to all terms of research participation. 5.Willing and able to participate in a recorded web-based video conferencing interview. 6.Cohort A (In Depth Interview): Has prescribed and treated at least two (2) patients with RRMM with talquetamab in a real-world setting. 7.Cohort B (Roundtable Discussion): Participated in talquetamab mono-therapy clinical trials (NCT04634552 and/or JRCT2061210001) and has treated at least two (2) patients with RRMM with talquetamab.

Exclusion criteria

Exclusion criteria: Any individual who does not meet all inclusion criteria.

Design outcomes

Primary

Measure	Time frame
As this study is qualitative in nature, typical outcome measures will not be collected for quantitative analysis. Key themes will include: 1) Talquetamab treatment strategies and administration practices (patient profiles, treatment sequencing, dosing schedules and modifications). 2) Mitigation, monitoring, and management of treatment-related AEs (including CRS, neurotoxicity, and GPRC5D-related AEs). 3) Evaluation of current and idealized administration models, and future best practices (e.g., combination therapies, use in earlier lines).	—

Measure

Time frame

As this study is qualitative in nature, typical outcome measures will not be collected for quantitative analysis. Key themes will include: 1) Talquetamab treatment strategies and administration practices (patient profiles, treatment sequencing, dosing schedules and modifications). 2) Mitigation, monitoring, and management of treatment-related AEs (including CRS, neurotoxicity, and GPRC5D-related AEs). 3) Evaluation of current and idealized administration models, and future best practices (e.g., combination therapies, use in earlier lines).

—

Countries

Japan

Contacts

Public ContactTetsuri Suzuki

INTAGE Healthcare Inc. Value & Access Department

suzuki.49352@intage.com03-5294-8393

Outcome results